Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 1
1996 2
1997 2
1998 1
2001 1
2002 4
2003 6
2004 2
2005 1
2006 6
2007 3
2008 3
2009 2
2010 5
2011 2
2012 7
2013 3
2014 9
2015 5
2016 3
2017 9
2018 13
2019 12
2020 8
2021 7
2022 13
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29666008

115 results

Results by year

Filters applied: . Clear all
Page 1
H2AFY is a novel fusion partner of MECOM in acute myeloid leukemia.
Han Q, Lu J, Wang J, Ye J, Jiang X, Chen H, Liu C, Chen L, Lin T, Chen S, Sun M, Gao F. Han Q, et al. Cancer Genet. 2018 Apr;222-223:9-12. doi: 10.1016/j.cancergen.2018.01.004. Epub 2018 Feb 17. Cancer Genet. 2018. PMID: 29666008 Free article.
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.
Baldazzi C, Luatti S, Zuffa E, Papayannidis C, Ottaviani E, Marzocchi G, Ameli G, Bardi MA, Bonaldi L, Paolini R, Gurrieri C, Rigolin GM, Cuneo A, Martinelli G, Cavo M, Testoni N. Baldazzi C, et al. Genes Chromosomes Cancer. 2016 Apr;55(4):375-88. doi: 10.1002/gcc.22341. Epub 2016 Jan 27. Genes Chromosomes Cancer. 2016. PMID: 26815134
Identification of novel MECOM gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review.
Connelly JA, Mody RJ, Wu YM, Robinson DR, Lonigro RJ, Vats P, Rabban E, Anderson B, Walkovich K. Connelly JA, et al. Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2):a002204. doi: 10.1101/mcs.a002204. Print 2018 Apr. Cold Spring Harb Mol Case Stud. 2018. PMID: 29572239 Free PMC article. Review.
Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R. Haas K, et al. Genes Chromosomes Cancer. 2008 Apr;47(4):288-98. doi: 10.1002/gcc.20532. Genes Chromosomes Cancer. 2008. PMID: 18181178
MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S, Morales-Camacho RM, Caballero-Velázquez T, Carrillo E, Sánchez J, Pérez-López O, Pérez de Soto I, González Campos J, Prats-Martín C, Bernal R, Vargas MT. Burillo-Sanz S, et al. Eur J Haematol. 2018 May;100(5):436-443. doi: 10.1111/ejh.13037. Epub 2018 Mar 1. Eur J Haematol. 2018. PMID: 29384595
Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
Gao J, Gurbuxani S, Zak T, Kocherginsky M, Ji P, Wehbe F, Chen Q, Chen YH, Lu X, Jennings L, Frankfurt O, Altman J, Sukhanova M. Gao J, et al. Genes Chromosomes Cancer. 2022 Feb;61(2):71-80. doi: 10.1002/gcc.23004. Epub 2021 Oct 28. Genes Chromosomes Cancer. 2022. PMID: 34668265
115 results